Key result
Serum magnesium levels did not significantly affect endothelial function or CIMT, although Ang-2 and BFMD predicted atherosclerosis early in hemodialysis patients (P=0.036 and P=0.006).
Why the study?
Cardiovascular disease is a major cause of mortality in dialysis patients, and low magnesium has been linked to increased mortality and endothelial function, prompting investigation into their relationship in patients on maintenance hemodialysis.
Is serum magnesium level associated with endothelial dysfunction and atherosclerosis markers in patients with ESRD on maintenance hemodialysis?
Cross-Sectional (n=85)
Is serum magnesium level associated with endothelial dysfunction and atherosclerosis markers in patients with ESRD on maintenance hemodialysis?
In patients with ESRD on hemodialysis, Ang-2 and BFMD can predict early atherosclerosis, but serum magnesium levels do not appear to affect these endothelial function markers.
Null findings for magnesium warrant no practice change in hemodialysis; Ang-2 and BFMD merit prospective validation as early atherosclerosis predictors.
Background Cardiovascular disease is a major cause of mortality in dialysis patients. Magnesium (Mg) level has been found to correlate positively with endothelial function. Moreover, it is suggested that low Mg is associated with increased all-cause and cardiovascular mortality in hemodialysis (HD) patients. Objective Therefore, this study was conducted to define the relationship between Mg level and endothelial dysfunction as an early marker of cardiovascular disease in patients with end-stage renal disease (ESRD) on maintenance HD. Patients and methods In this cross-sectional study, 85 patients with ESRD on maintenance HD were included. Serum angiopoietin-2 (Ang-2) level, brachial flow-mediated dilation (BFMD), and carotid intima-media thickness (CIMT) were measured as indicators of endothelial dysfunction and atherosclerosis. Patients’ serum Mg levels were measured. All data are presented as mean and SD or percent frequency. Statistical tests, mainly t test, Mann–Whitney test, or χ 2 test, are used in comparison between groups for quantitative and qualitative data correspondingly. Results Our results indicate that Ang-2 and BFMD are associated and can predict atherosclerosis early in HD patients ( P =0.036 and 0.006, respectively). When the patients were divided according to their serum Mg, there was no significant difference regarding Ang-2, BFMD, and CIMT between the two groups. Conclusion This study demonstrated that endothelial dysfunction markers such as Ang-2 and BFMD are associated and can predict atherosclerosis early in HD patients. On the contrary, Mg might not affect neither endothelial function (FMD and Ang-2) nor CIMT as a marker of atherosclerosis in ESRD on HD.
No takes yet. Share an insight, caveat, or question.
Alia et al. (2021) conducted a cross-sectional in end-stage renal disease (ESRD) on maintenance hemodialysis (n=85). Serum magnesium level vs. Different serum magnesium groups was evaluated on Endothelial dysfunction (Ang-2, BFMD) and atherosclerosis (CIMT). Serum magnesium levels did not significantly affect endothelial function or CIMT, although Ang-2 and BFMD predicted atherosclerosis early in hemodialysis patients (P=0.036 and P=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: